Objective response rate ( P = 0.003 ) , duration of response ( P = 0.0027 ) , depth of response ( P = 0.0149 ) , progression-free survival ( PFS ; P = 0.0015 ) and overall survival ( OS ; P = 0.0057 ) were improved in the panitumumab + FOLFOX4 group .